Brain Metastases in EGFR- and ALK-Positive Lung Cancer: Giving Radiotherapy Upfront

Brain Metastases Are No Longer Just a “Late Complication,” but Central to Treatment Strategy

Brain metastases are common and clinically decisive in non-small cell lung cancer. As survival in patients with EGFR mutations or ALK fusions has increased with modern targeted therapies, control of the central nervous system has become even more important. A patient may be doing well systemically while developing progression only in the brain; this can mean a treatment change, radiotherapy, steroid use, and neurological loss.

In the past, radiotherapy was often introduced early when brain metastases were detected. However, after newer-generation TKIs with strong brain penetration, such as osimertinib, alectinib, brigatinib, and lorlatinib, became available, a new strategy emerged: start TKI treatment first in asymptomatic, small, and monitorable brain metastases, and defer radiotherapy until progression.

This approach is attractive to patients because the potential neurocognitive effects of radiotherapy, radiation necrosis, fatigue, and treatment burden can be delayed. The risk, however, is that if intracranial disease control is lost, the patient may later face symptomatic, more extensive, or more difficult-to-manage intracranial progression.

Upfront RT + TKI Strategy Versus Delayed RT Strategy

The study compared an early cranial radiotherapy strategy with a delayed radiotherapy strategy in patients with metastatic NSCLC carrying driver mutations such as EGFR or ALK and with asymptomatic brain metastases. Patients were divided into two main arms: upfront RT and delayed RT.

Early Radiotherapy Substantially Reduced Intracranial Progression

The study's most striking result concerned intracranial progression, meaning progression of disease within the brain. Median follow-up was approximately 30,6 months . There were 20 intracranial progression events in the upfront RT arm, compared with 47 in the delayed RT arm.

The one-year intracranial progression rate in the upfront RT arm was %8,7, and in the delayed RT arm it was %25,7 . The two-year rates separated more markedly: in the upfront RT arm the rate was %21,7, and in the delayed RT arm it was %50,0. The subdistribution hazard ratio was reported as 0,35 and the P value was <0,001 .

Intracranial PFS Is Numerically Better, but Not Statistically Significant

Intracranial progression-free survival expresses the time without intracranial disease progression or death. According to the slide data, median intracranial PFS in the upfront RT arm was 18,2 months, and in the delayed RT arm it was 14,8 months . The two-year intracranial PFS rate with upfront RT was reported as %38,3, and with delayed RT as %30,8 .

However, the hazard ratio was 0,82and the P value was 0,26 ; thus, no statistically significant difference in intracranial PFS was demonstrated. This may appear contradictory: intracranial progression is substantially reduced, but icPFS is not significant. The reason is that icPFS is also affected by events outside the brain, such as death, and the overall course of disease is not limited to intracranial control.

Brain Control Improved, but Overall PFS and OS Have Not Changed So Far

No difference in overall progression-free survival was seen between the two arms. Median PFS in the upfront RT arm was 12,7 months, and in the delayed RT arm it was 12,0 months . The hazard ratio was reported as 1,05and the P value as 0,75 . This shows that early brain radiotherapy did not substantially change whole-body disease control.

No significant superiority in overall survival was identified either. Median OS in the upfront RT arm was 23,3 months, and in the delayed RT arm it was 28,7 months . The HR was 1,45and the P value was 0,07 . Although this number appears to favor delayed RT, it is not statistically significant and should be interpreted carefully.

Radiotherapy Was Central First; Then TKIs Crossed the Brain Barrier

Historically, radiotherapy played a very central role in treating brain metastases. Whole-brain radiotherapy for multiple brain metastases and stereotactic radiosurgery for limited metastases were the main local treatment options for many years. However, the neurocognitive adverse effects of whole-brain radiotherapy became an important problem, particularly in patients living for a long time.

The development of EGFR- and ALK-targeted therapies changed this field. Brain control was more limited in the era of first-generation TKIs, but central nervous system efficacy increased substantially with osimertinib and newer-generation ALK inhibitors. Thus, in asymptomatic brain metastases, the strategy of monitoring on a TKI and using RT when needed, instead of giving radiotherapy upfront, was increasingly discussed.

Which Patients Should Receive Upfront RT, and Which Should Be Managed with Watchful Waiting?

This study does not provide a single answer for all patients. Brain metastasis management depends not only on mutation status but also on the number, size, and location of metastases, the presence of edema, the patient's symptoms, the CNS efficacy of the TKI used, extracranial disease burden, and the reliability of patient follow-up.

Early RT may be more attractive in patients at high risk of recurrence within the brain. Conversely, a delayed RT strategy may still be reasonable in patients with a small number of small, asymptomatic metastases, who are using a TKI with strong CNS efficacy and can undergo close brain MRI follow-up.

The Study's Strongest and Most Limited Message

The strongest message of the study is that early cranial radiotherapy substantially reduces the risk of intracranial progression. The decrease in the intracranial progression rate from 50,0% to 21,7% at 2 years is clinically meaningful. Brain progression is not merely an imaging finding; it can have serious effects on the patient's neurological function, need for steroids, need for emergency treatment, and quality of life.

The most limited message, however, is that this control advantage has not yet translated into overall PFS or overall survival. Early RT may protect the brain better, but it does not show a substantial advantage in the patient's total survival time or whole-body disease course. Decisions should therefore be based on “brain control, quality of life, safety of follow-up, and treatment burden” rather than a “survival advantage.”

The Brain Control Gain Is Clear; the Survival Message Is Not Yet Clear

Critical Issues Awaiting Answers

The Era of Timing in Brain Metastases: No Single Answer for Every Patient

The phase 3 randomized study presented at ASCO 2026 shows that early cranial radiotherapy substantially reduces intracranial progression in patients with EGFR/ALK-positive NSCLC and asymptomatic brain metastases. The two-year intracranial progression rate was 21,7% with upfront RT and 50,0% with the delayed RT strategy; the sub-HR of 0,35 and P<0,001 demonstrate a strong advantage in brain control.

However, the same study does not show a significant advantage in overall PFS or overall survival. Median PFS is similar at approximately 12 months; although median OS appears numerically longer in the delayed RT arm, it does not reach statistical significance. The study therefore conveys “upfront RT reduces brain progression,” rather than “upfront RT prolongs survival.”

In clinical practice, this result shows that we should further personalize radiotherapy timing. Early RT should be considered more strongly in patients with high intracranial disease burden, critical lesion locations, or follow-up difficulties. For small, asymptomatic lesions that can be closely followed with MRI, a delayed RT strategy with a TKI with strong CNS efficacy may still be reasonable. In modern lung cancer practice, the question is no longer simply “Should we give radiotherapy?”, but “To which patient, at what time, with which technique, and with which brain control goal should we give it?”